VYNE Therapeutics Reports Officer/Director Changes, Comp Arrangements

TL;DR

**VYNE Therapeutics just announced leadership changes and new pay deals, watch for strategic shifts.**

AI Summary

VYNE Therapeutics Inc. filed an 8-K on January 3, 2024, reporting an event that occurred on December 29, 2023. The filing indicates a change in directors or officers and compensatory arrangements, along with a Regulation FD Disclosure. This matters to investors because changes in leadership and executive compensation can signal shifts in company strategy or financial health, potentially impacting future stock performance.

Why It Matters

Changes in executive leadership and compensation can influence a company's strategic direction and operational efficiency, directly affecting investor confidence and stock valuation.

Risk Assessment

Risk Level: medium — Changes in leadership can introduce uncertainty, but the specific details of the changes and compensation are not fully disclosed in this summary, making the impact unclear.

Analyst Insight

Investors should monitor subsequent filings or company announcements for specific names, roles, and compensation details related to the reported changes to assess potential strategic impacts.

Key Players & Entities

• VYNE Therapeutics Inc. (company) — the registrant filing the 8-K
• December 29, 2023 (date) — date of the earliest event reported
• January 3, 2024 (date) — date the 8-K was filed
• Delaware (company) — state of incorporation for VYNE Therapeutics Inc.
• 001-38356 (dollar_amount) — Commission File Number

Forward-Looking Statements

• VYNE Therapeutics Inc. will provide more specific details regarding the leadership changes and compensatory arrangements in future filings or press releases. (VYNE Therapeutics Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — e on which registered Common Stock, $0.0001 par value VYNE The Nasdaq Stock Mar
• $2.33 — n stock with an exercise price equal to $2.33 per share. This option award will vest
• $40,000 — ve the standard annual cash retainer of $40,000, payable quarterly. Dr. Borowski has al

Filing Documents

• tm2333851d1_8k.htm (8-K) — 28KB
• tm2333851d1_ex99-1.htm (EX-99.1) — 8KB
• tm2333851d1_ex99-1img001.jpg (GRAPHIC) — 22KB
• 0001104659-24-000584.txt ( ) — 241KB
• vyne-20231229.xsd (EX-101.SCH) — 3KB
• vyne-20231229_lab.xml (EX-101.LAB) — 33KB
• vyne-20231229_pre.xml (EX-101.PRE) — 22KB
• tm2333851d1_8k_htm.xml (XML) — 3KB

02. Departure of Directors or Certain Officers; Election

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. As previously disclosed, in connection with VYNE Therapeutics Inc.'s (the "Company") private placement financing on November 1, 2023, the Company agreed to appoint one designee of Access Industries, Inc. ("Access Bio") to the Board of Directors (the "Board") of the Company. On December 29, 2023, the Board appointed Dr. Christine Borowski to serve as a Class II director of the Company, effective as of January 1, 2024, for a term continuing to the Company's 2026 annual meeting of stockholders and until her successor is appointed. The Board has determined that Dr. Borowski satisfies the definition of an "independent director" under the Nasdaq Stock Market listing standards and applicable U.S. Securities and Exchange Commission ("SEC") rules. Dr. Borowski, age 46, has served as Vice President at Access Bio since January 2022, and previously served as Senior Associate beginning in July 2019. Prior to that, Dr. Borowski worked on therapeutics company creation at Apple Tree Partners from 2017 to May 2019. Before joining Apple Tree Partners, Dr. Borowski worked as an editor at several high-impact scientific journals, most recently as Chief Editor of Nature Medicine from 2014 to 2017. She earned a B.S. in Biology at the University of Kentucky, a Ph.D. in Immunology at Harvard University, and completed her postdoctoral work on natural killer T cell development at the University of Chicago. In connection with her appointment, pursuant to the Company's non-employee director compensation policy, Dr. Borowski was granted an option to purchase 40,000 shares of the Company's common stock with an exercise price equal to $2.33 per share. This option award will vest annually over three years on the anniversary of the date of grant, subject to her continued service to the Company through each vesting date. In addition, followin

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 3, 2024, the Company issued a press release announcing Dr. Borowski's appointment to the Board. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated January 3, 2024. 104 Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VYNE THERAPEUTICS INC . Date: January 3, 2024 By: /s/ Mutya Harsch Mutya Harsch Chief Legal Officer and General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR